You are here

J&J to pay US$2.2b in fines for improper marketing of drug

Firm acknowledges it promoted anti-psychotic drug for unapproved uses

[NEW YORK] Johnson & Johnson has agreed to pay more than US$2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the anti-psychotic drug Risperdal to older adults, children and people with developmental disabilities, the Justice Department said.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to